Marc Chevrier
Overview
Explore the profile of Marc Chevrier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
918
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chevrier M, Frugier A, Colognac S, Monneret D
Clin Chem Lab Med
. 2024 Jul;
63(1):e16-e20.
PMID: 38982754
No abstract available.
2.
Jordan J, Benson J, Chatham W, Furie R, Stohl W, Cheng-Chung Wei J, et al.
Lancet Rheumatol
. 2024 Jan;
2(10):e613-e622.
PMID: 38273624
Background: Activation of the type I interferon (IFN) pathway is associated with systemic lupus erythematosus (SLE). We assessed the safety and tolerability of JNJ-55920839, a human monoclonal antibody that selectively...
3.
Monneret D, Moreau A, Chirica C, Guergour D, Richet C, Desmurs L, et al.
Clin Biochem
. 2023 Feb;
114:63-66.
PMID: 36773631
Objectives: Non-linearity in lipase assays and the ensuing gaps in results distribution have been described on Roche analysers, but have yet to be studied on other analysers. Design And Methods:...
4.
van Vollenhoven R, Hahn B, Tsokos G, Lipsky P, Gordon R, Fei K, et al.
J Rheumatol
. 2021 Dec;
49(4):380-387.
PMID: 34853089
Objective: To evaluate the long-term efficacy and safety of ustekinumab through 2 years in patients with active systemic lupus erythematosus (SLE). Methods: This was a placebo-controlled (week 24), phase II...
5.
Nadejde N, Lemseffer Y, Desmurs L, Zaepfel S, Kaczorowski F, Poitevin-Later F, et al.
Clin Chem Lab Med
. 2021 Jul;
59(12):e438-e441.
PMID: 34291619
No abstract available.
6.
Kamel S, Raynor A, Zozor S, Lacape G, Brunel V, Nivet-Antoine V, et al.
Ann Biol Clin (Paris)
. 2021 Jun;
79(3):219-231.
PMID: 34165431
Covid-19 is responsible for myocardial injury in many infected patients, which is associated with severe disease and critical illness. The mechanisms by which SARS-CoV-2 may cause myocardial damage involve direct...
7.
Seridi L, Cesaroni M, Orillion A, Schreiter J, Chevrier M, Marciniak S, et al.
Lupus
. 2021 Feb;
30(5):795-806.
PMID: 33626969
Objectives: We aimed to identify transcriptional gene signatures predictive of clinical response, for pharmacodynamic evaluation, and to provide mechanistic insight into JNJ-55920839, a human IgG1κ neutralizing mAb targeting IFN-α/IFN-ω, in...
8.
Turiello R, Capone M, Giannarelli D, Morretta E, Monti M, Madonna G, et al.
J Immunother Cancer
. 2020 Dec;
8(2).
PMID: 33361405
Background: Inhibitors of immune checkpoint programmed cell death protein 1 (PD-1) receptor on T cells have shown remarkable clinical outcomes in metastatic melanoma. However, most patients are resistant to therapy....
9.
Yao Z, Loggia L, Fink D, Chevrier M, Marciniak S, Sharma A, et al.
Clin Drug Investig
. 2020 Oct;
40(12):1127-1136.
PMID: 33085033
Background: The interferon (IFN) pathway has been correlated with clinical and serological markers of disease activity in patients with systemic lupus erythematosus (SLE). Objective: The pharmacokinetics and pharmacodynamics of JNJ-55920839,...
10.
Cesaroni M, Seridi L, Loza M, Schreiter J, Sweet K, Franks C, et al.
Arthritis Rheumatol
. 2020 Oct;
73(3):472-477.
PMID: 33010188
Objective: In a previously reported phase II randomized, placebo-controlled, interventional trial, we demonstrated that treatment with ustekinumab, an anti-interleukin-12 (IL-12)/IL-23 p40 neutralizing monoclonal antibody, improved global and organ-specific measures of...